Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 3c
August 11, 2021 4:04 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of ($0.51), $0.03 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $2.33 million.
Mr. Ian Mortimer, Xenons President and Chief Executive Officer stated, We continue to make strong progress across our portfolio of... More
